Form 4: Lenz Therapeutics Executive Exercises Stock Options
SEC Form 4 Filing
Shawn Olsson, Chief Commercial Officer of Lenz Therapeutics, exercised stock options and acquired 1,400 shares of common stock at a price of $2.08 on April 9, 2025.
Summary
- On April 9, 2025, Shawn Olsson, the Chief Commercial Officer of Lenz Therapeutics, exercised stock options.
- This transaction resulted in the acquisition of 1,400 shares of common stock at a price of $2.08 per share.
- Following the transaction, Olsson directly owns 4,733 shares of Lenz Therapeutics common stock.
- Olsson also holds options to purchase 63,241 shares of common stock.
Sentiment
Score: 5
Explanation: This is a neutral event, simply reporting a transaction by an officer. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This is a standard SEC Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company executives.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it represents a routine exercise of stock options by an executive.
Key Dates
| Date | Description |
|---|---|
| 04/26/2021 | Vesting Commencement Date for the stock options. |
| 08/18/2031 | Expiration date of the stock options. |
| 04/09/2025 | Date of the transaction: exercise of stock options and acquisition of common stock. |
Keywords
LENZ Therapeutics, stock options, Form 4, Shawn Olsson, Chief Commercial Officer, insider trading, securities, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.